The Tribiosys Business
Management Team has significant expertise in the biopharmaceutical,
healthcare and systems integration verticals. In the course
of their careers, the team has successfully delivered mission-critical,
enterprise-wide, supply chain optimization solutions to
over a hundred Fortune 500 companies.
Samir Bhatia, M.S.
Tribiosys Advisory Board is composed of several industry
Richard W. Barker, D.Phil.
Susan J. Ward,
Samir Bhatia, M.S.
Mr. Bhatia has over 15 years
of experience in technology based companies. Mr. Bhatia
is responsible for Operations and Partnerships at Tribiosys.
Before joining Tribiosys, Mr. Bhatia was founder and CTO
of StructuredMarkets, Inc., an online equity marketplace.
At Systems Engineering Associates, Mr. Bhatia managed Internet/e-commerce
project marketing and sales. Prior to SEA, Samir managed
the turnaround of Xscribe Corporation, as general manager
overseeing product design and development, sales and marketing,
and support functions. Mr. Bhatia has a MS degree in Computer
Science and an MS degree in Physics from Northeastern University.
Dr. Barker has over a decade of experience managing
health care and medical informatics organizations. Dr. Barker
held executive committee positions at Chiron, a $900 million
biopharmaceutical company. His first position was as president
and chief executive of Chiron's largest division, the $600m
diagnostics business, before its sale to Bayer Corporation.
Subsequently, he served as senior vice president responsible
for corporate strategy and business development, including
M&A and technology licensing. Before Chiron, Dr. Barker
developed healthcare IT solutions as general manager of
IBM's $2B worldwide healthcare business. Previously, Dr.
Barker led McKinsey & Company's European healthcare
practice. Dr. Barker sits on the Boards of Sunquest Information
Systems (a laboratory information company) and EXACT Sciences,
an applied genomics company. He received a BA in Chemistry
and DPhil in Biophysics, both from Oxford University, UK.
Mr. Anand has over 12 years of experience
in business strategy, business process, information technology,
and data management systems consulting. Before founding
Tribiosys, Mr. Anand was a founding partner at Usheron Ventures,
LLC, a provider of funding and strategic guidance to technology
start-ups. Prior to Usheron, Mr. Anand was the president
and founder of International Integration, Inc. (NASDAQ:
ICUB), which merged with Razorfish, Inc. (NASDAQ: RAZF)
in November 1999. At the time of the merger, I-Cube had
$70 million in revenues, with 600 consultants and 6 offices
across the United States and Europe. Mr. Anand holds a MS
in Computer Science from Northeastern University.
Dr. Shivdasani is an assistant
professor of Medicine at Dana-Farber Cancer Institute and
Harvard Medical School. His training includes Internal Medicine
at Brigham & Women's Hospital, Medical Oncology at the
Dana-Farber Cancer Institute, and post-doctoral research
training at Children's Hospital in Boston. His current research
on the molecular basis of mammalian development and cell
differentiation is funded through the National Institutes
of Health and charitable foundations. A member of several
professional societies, Dr. Shivadasani has published many
original papers and is board certified in Internal Medicine
and Medical Oncology. He holds MD and PhD degrees from the
University of Michigan.
Vikrant Raina, M.B.A.
Mr. Raina is a director of Boston Ventures, LP, a private
equity firm located in Boston, MA. Previous to joining Boston
Ventures, Mr. Raina served as executive director in the
Communications, Media and Technology group at Goldman Sachs
(Asia), LLC. Prior to that, Mr. Raina worked in the Communications
and High Technology practice for The Boston Consulting Group,
Inc. He holds a BS degree from Yale University and a MBA
with distinction from Harvard Graduate School of Business
Mr. Gentile, Vice President and General Manager of BD Biosciences
Discovery Labware, has over 20 years of experience in the
high-technology medical device and life sciences industry.
He was responsible for the strategic and operational restructuring
of the company by re-focusing the business on the higher
growth areas of drug discovery and proteomics while further
developing, revitalizing and strengthening the core business
of tissue culture and fluid handling. As a member of the
BD Biosciences Leadership Team, he has joint responsibility
for overall business performance and development including,
business alliances, acquisitions and portfolio management.
Prior to joining BD (Becton, Dickinson and Company), of
which BD Biosciences is one of four business segments, Mr.
Gentile served as a member of Hewlett-Packard's core management
team responsible for the determination of customer needs,
product requirements and business structure for a major
new business start up. During his tenure with Hewlett-Packard,
he was responsible for the design and implementation of
the Medical Group's Global Technology Strategy and management
of a group-wide task force chartered with the design of
a comprehensive resource allocation model for project, program
and portfolio valuation. Mr. Gentile graduated from Northeastern
University with a Bachelor of Science in electrical engineering
and a minor in biology. He received a Master of Science
and a Master of Business Administration, graduating Summa
Cum Laude, from Boston University.
Shiv Tasker, a partner with Emsan Consulting, heads the
start up and emerging growth company practice with focus
on business and marketing strategy.
Prior to Emsan Consulting, Shiv was the president
and CEO of Phase Forward, a software and service solution
vendor for the data collection and management of clinical
trials of new drugs and devices.
Prior to Phase Forward, Shiv was Sr.
Vice President for Worldwide Sales, Consulting Services
and Corporate Marketing at Viewlogic Systems Inc, a supplier
of complex electronic design automation tools for Integrated
Circuit and Printed Circuit Board design.
As SVP of Sales, Viewlogic had successive quarters
of record growth ($200M run rate) till the company’s sale
to a larger competitor.
He improved service gross
margins from 27% to 62% within 6 quarters and successfully
branded the company away from its historical slower growing
products to a new set of hot growth products that led to
the company being viewed as a serious acquisition target.
Mr. Tasker spent 8 years at Cadence Design Systems in a
variety of roles in marketing and general management with
ever increasing responsibility for product lines and larger
to Cadence, he was with Intergraph Corp for 5.5 years, initially
as a programmer and later as a marketer.
Tasker holds an MBA from the University of Texas at Arlington
and a BS from the University of Bombay in Statistics and
Economics. He is a member of the Drug Information Association
and works with the Youth Technology Entrepreneurs, a non-profit
organization aimed at enriching high school curriculums
with real life technology skills – primarily in lower income
school districts. He was recently honored by
Mass Hi-Tech as an All-Star.
J. Ward, Ph.D.
Executive Advisor to Biotech, their
Investors and Suppliers
Dr. Ward has over 20 years operational experience in major
Pharma and as a corporate office in successful Biotech,
with responsibilities in drug discovery and development,
supporting technology and process development, and corporate
Educated as a research scientist in central nervous system
disorders, Susan began her research career at Sterling Drug
in 1982. In 1993, she joined Wyeth Research as Vice President
of Research (UK) and Vice President of CNS Disorders worldwide.
Adopting responsibility for Project Management and the Wyeth
Drug Development Portfolio in 1996, Susan oversaw the development
of 30+ new and life cycle extension products, including
global approvals for Enbrel, Mylotarg, Sonata, Rapamune
and Protonix, and label extensions for Efexor and Women’s
Health products. She established one of the first project
management capabilities in drug discovery in the industry,
halving time to first studies in man, and improving productivity
in several steps in the development process.
Joining the corporate senior team of Millennium Pharmaceuticals
Inc. in 2000, Susan led the evolution of Millennium’s successful
genome technology platform into downstream R&D areas,
established knowledge management capability, and integrated
these into a comprehensive Productivity strategy and platform.
Susan worked with Infinity Pharmaceuticals, first as an
advisor to its inception and early start-up, and than as
Executive Vice President establishing a cutting-edge and
integrated platform operational and strategic platform designed
to aid productivity of both scientists and business functions.
Dr. Ward is now an Executive Advisor to Biotechnology, sometimes
joining the senior management team of a company at a strategic
transition point for an interim period of time. She is the
founding CSO of ThoughLynx, a software company dynamically
integrating disparate information sources for the Life Sciences,
and serves on the Advisory Boards of Timeblaster, Ingenuity,
and Business Engine software companies. Susan established
the initial research strategy and plan for Alnylam Pharmaceuticals,
a leading RNA-interference company, and undertakes shorter
consults in Biotech, recent clients including Viropharma,
Adolor, Structural Genomics, and several venture capital